Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma

Full text
Author(s):
Show less -
Figueiredo, Carlos R. [1, 2] ; Azevedo, Ricardo A. [2] ; Mousdell, Sasha [1] ; Resende-Lara, Pedro T. [3, 4] ; Ireland, Lucy [1] ; Santos, Almudena [1] ; Girola, Natalia [2] ; Cunha, Rodrigo L. O. R. [5] ; Schmid, Michael C. [1] ; Polonelli, Luciano [6] ; Travassos, Luiz R. [2] ; Mielgo, Ainhoa [1]
Total Authors: 12
Affiliation:
[1] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside - England
[2] Fed Univ Sao Paulo UNIFESP, Dept Microbiol Immunol & Parasitol, Expt Oncol Unit UNONEX, Sao Paulo - Brazil
[3] Fed Univ ABC, Lab Computat Biol & Bioinformat, Santo Andre - Brazil
[4] Ecole Normale Super, UMR 8113, LBPA, Cachan - France
[5] Fed Univ ABC, Nat & Human Sci Ctr, Chem Biol Lab, Santo Andre - Brazil
[6] Univ Parma, Dept Med & Surg, Unit Biomed Biotechnol & Translat Sci, Parma - Italy
Total Affiliations: 6
Document type: Journal article
Source: FRONTIERS IN IMMUNOLOGY; v. 9, MAY 23 2018.
Web of Science Citations: 6
Abstract

Mounting an effective immune response against cancer requires the activation of innate and adaptive immune cells. Metastatic melanoma is the most aggressive form of skin cancer. While immunotherapies have shown a remarkable success in melanoma treatment, patients develop resistance by mechanisms that include the establishment of an immune suppressive tumor microenvironment. Thus, understanding how metastatic melanoma cells suppress the immune system is vital to develop effective immunotherapies against this disease. In this study, we find that macrophages (MOs) and dendritic cells (DCs) are suppressed in metastatic melanoma and that the Ig-CDR-based peptide C36L1 is able to restore MOs and DCs' antitumorigenic and immunogenic functions and to inhibit metastatic growth in lungs. Specifically, C36L1 treatment is able to repolarize M2-like immunosuppressive MOs into M1-like antitumorigenic MOs, and increase the number of immunogenic DCs, and activated cytotoxic T cells, while reducing the number of regulatory T cells and monocytic myeloid-derived suppressor cells in metastatic lungs. Mechanistically, we find that C36L1 directly binds to the MIF receptor CD74 which is expressed on MOs and DCs, disturbing CD74 structural dynamics and inhibiting MIF signaling on these cells. Interfering with MIF-CD74 signaling on MOs and DCs leads to a decrease in the expression of immunosuppressive factors from MOs and an increase in the capacity of DCs to activate cytotoxic T cells. Our findings suggest that interfering with MIF-CD74 immunosuppressive signaling in MOs and DCs, using peptide-based immunotherapy can restore the antitumor immune response in metastatic melanoma. Our study provides the rationale for further development of peptide-based therapies to restore the antitumor immune response in metastatic melanoma. (AU)

FAPESP's process: 15/23898-8 - Evaluation of tumour associated macrophages M1 and M2 in response to the anti-tumour C36L1 peptide
Grantee:Carlos Rogerio de Figueiredo
Support type: Scholarships abroad - Research Internship - Post-doctor